ThermoGenesis Holdings, Inc. (THMO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ThermoGenesis Holdings, Inc. (THMO) trades at $0.0001 with AI Score 49/100 (Grade C). ThermoGenesis Holdings, Inc. is a leading innovator in automated cell processing systems for medical applications. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for THMO: THMO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates THMO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
THMO: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
ThermoGenesis Holdings, Inc. (THMO) Healthcare & Pipeline Overview
ThermoGenesis Holdings, Inc. specializes in automated systems for cell banking and processing, offering innovative solutions that cater to the growing demand for cell-based therapies in clinical settings worldwide.
What Is the Investment Thesis for THMO?
ThermoGenesis Holdings, Inc. operates in a rapidly growing sector, with a focus on automated cell processing systems that are increasingly vital in healthcare. The global market for cell-based therapies is expanding, driven by advancements in regenerative medicine and personalized healthcare. As of now, ThermoGenesis's gross margin stands at 20.4%, which, while below industry averages, reflects the company's investment in R&D and product innovation. The company’s unique offerings, such as the AXP II and BioArchive systems, position it well to capture market share in the bio-banking and therapeutic segments. However, the company faces challenges, including a profit margin of -190.3%, indicating significant operational losses that need to be addressed. The leadership under CEO Xiaochun Xu is pivotal, as strategic decisions in product development and market expansion could enhance profitability and operational efficiency. Investors should monitor the company's ability to navigate its financial challenges while leveraging growth opportunities in the cell therapy market.
Based on FMP financials and quantitative analysis
THMO Key Highlights
Market Cap: $0.00B, indicating a micro-cap status with potential for growth.
- Gross Margin: 20.4%, reflecting the company's current operational efficiency in the medical devices sector.
- Profit Margin: -190.3%, highlighting significant operational losses that need addressing.
- Beta: 8.03, indicating a high level of volatility compared to the market.
- No dividend yield, as the company is reinvesting in growth and development.
Who Are THMO's Competitors?
THMO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CERC Cerecor Inc. | $2.93 | -1.68% | $38.6M | 50 |
| FATE Fate Therapeutics, Inc. | $2.65 | +3.52% | $309M | — |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are THMO's Key Strengths?
Innovative product line tailored for automated cell processing.
- Established presence in key international markets.
- Strong focus on R&D leading to continuous product improvement.
What Are THMO's Weaknesses?
Negative profit margin indicating operational challenges.
- Limited brand recognition compared to larger competitors.
- Small workforce may limit operational scalability.
What Could Drive THMO Stock Higher?
Launch of new automated systems for cell processing expected in Q4 2026.
- Expansion of distribution partnerships in emerging markets.
- Continued investment in R&D for innovative cell therapy solutions.
What Are the Key Risks for THMO?
Financial-distress signal — its Altman Z-Score of -41.88 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges that could delay product approvals.
- High operational losses impacting financial stability.
- Intense competition from larger, well-established companies.
What Are the Growth Opportunities for THMO?
- Expansion into Emerging Markets: ThermoGenesis has the opportunity to expand its reach into emerging markets such as Southeast Asia and Africa, where the demand for cell-based therapies is on the rise. With a projected market size of $10 billion for cell therapies in these regions by 2030, the company can leverage its innovative products to capture a share of this growing market.
- Partnerships with Healthcare Providers: Collaborating with hospitals and surgical centers to integrate ThermoGenesis's point-of-care systems can enhance product adoption. As healthcare providers increasingly seek efficient solutions for stem cell processing, establishing partnerships can lead to increased sales and market penetration, potentially driving revenue growth by 15-20% over the next five years.
- Advancements in Product Development: Continued investment in R&D to enhance existing products and develop new solutions can position ThermoGenesis as a leader in the automated cell processing market. With an estimated global market size of $5 billion for automated cell processing systems by 2028, innovation could significantly boost the company’s market share.
- Regulatory Approvals for New Therapies: Gaining regulatory approvals for new cell-based therapies can open up additional revenue streams. As the regulatory landscape evolves, successful navigation could lead to new product launches and increased market opportunities, potentially contributing to a 10% annual revenue growth.
- Increased Demand for CDMO Services: The rising demand for contract development and manufacturing services in the cell therapy sector presents a significant growth opportunity. As more companies seek to outsource their development needs, ThermoGenesis can capitalize on this trend, potentially increasing its CDMO revenue by 25% over the next three years.
What Threats Does THMO Face?
- Intense competition from established players and startups.
- Regulatory challenges in bringing new products to market.
- Market volatility affecting funding and investment opportunities.
What Are THMO's Competitive Advantages?
- Innovative product offerings that cater to specialized needs in cell processing.
- Established reputation in the biomedical sector with a history of innovation.
- Strong focus on R&D to continuously improve and expand product lines.
- Global distribution network that enhances market accessibility.
What Does THMO Do?
Founded in 1986 and headquartered in Rancho Cordova, California, ThermoGenesis Holdings, Inc. is a pioneering company in the field of automated systems for cell-banking, cell-processing, and cell-based therapeutic applications. Over the years, the company has evolved from its original identity as Cesca Therapeutics Inc. to become a recognized name in the biomedical sector, officially adopting its current name in November 2019. ThermoGenesis's product portfolio is extensive, featuring advanced medical devices essential for automated cell processing. The AXP II Automated Cell Separation System is a key offering, designed to isolate stem and progenitor cells from umbilical cord blood within a fully closed system, ensuring safety and efficiency. Complementing this is the BioArchive Automated Cryopreservation System, which provides robotic, liquid nitrogen-controlled freezing and long-term storage solutions for cord blood samples and other cell therapeutic products. The company also addresses point-of-care applications with the XP Point-of-Care System, facilitating the rapid processing of autologous stem cells in clinical environments. Additionally, the PXP-1000 System enhances the separation of cellular components from blood with minimal contamination. For laboratory use, ThermoGenesis offers the X-Series cell processing products, which include X-Lab, X-Wash System, and X-Mini, catering to various cell isolation and purification needs. Beyond its product offerings, ThermoGenesis provides contract development and manufacturing (CDMO) services tailored to cell and cell-based gene therapies, showcasing its commitment to innovation in the healthcare sector. The company markets its products through independent distributors and directly to end-user customers, establishing a robust presence in the United States, China, the United Arab Emirates, Vietnam, and other international markets.
What Products and Services Does THMO Offer?
- Develop automated systems for cell banking and processing.
- Provide advanced medical devices for isolating stem cells from umbilical cord blood.
- Offer robotic cryopreservation systems for long-term storage of biological samples.
- Deliver point-of-care solutions for rapid processing of autologous stem cells.
- Market products through independent distributors and directly to end-users.
- Provide contract development and manufacturing services for cell therapies.
How Does THMO Make Money?
- Generate revenue through the sale of automated cell processing systems and medical devices.
- Offer CDMO services for cell-based therapies, providing additional revenue streams.
- Market products globally, focusing on regions with high demand for cell banking and processing solutions.
- Utilize a network of independent distributors to enhance market reach and customer access.
What Industry Does THMO Operate In?
The medical devices industry is experiencing significant growth, driven by advancements in technology and increasing demand for innovative healthcare solutions. The global market for cell-based therapies is projected to expand as personalized medicine gains traction, with a focus on regenerative therapies and bio-banking. ThermoGenesis Holdings, Inc. is strategically positioned within this landscape, offering specialized products that cater to the needs of healthcare providers and researchers. The competitive landscape includes established players and emerging startups, all vying for market share in this rapidly evolving sector. As the industry continues to grow, companies like ThermoGenesis must innovate and adapt to maintain their competitive edge.
Who Are THMO's Key Customers?
- Hospitals and surgical centers requiring point-of-care cell processing solutions.
- Biobanks and research institutions focused on stem cell research and storage.
- Companies developing cell-based therapies seeking CDMO services.
- Healthcare providers in emerging markets looking for innovative medical devices.
Company Profile
ThermoGenesis Holdings, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Rancho Cordova, US. The company is led by CEO Xiaochun Xu. THMO has traded publicly since 1987.
How ThermoGenesis Holdings, Inc. Is Valued
Relative to its peer group, THMO's quantitative score of 49/100 is below the peer average of 61/100.
Financial Health
ThermoGenesis Holdings, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -41.88 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
ThermoGenesis Holdings, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 6332.4% below estimates on average.
Forward Outlook
Wall Street analysts project ThermoGenesis Holdings, Inc. revenue of about $24.6M for fiscal 2026, with EPS near $0.31.
THMO Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approaches in the regenerative medicine space.
- ThermoGenesis has made strides in partnerships that enhance its market position, reflecting a growing recognition of its technologies.
- Increased media coverage has spotlighted the company's advancements, attracting interest from investors and enhancing its visibility in the market.
Bear Case
- Concerns linger regarding the company's ability to scale operations effectively, raising questions about long-term sustainability.
- Despite positive sentiment, some community members express skepticism about the competitive landscape and the company's differentiation.
- Recent earnings reports have shown mixed results, leading to uncertainty about future profitability and growth trajectories.
- Market volatility has made investors cautious, with some bearish sentiments reflecting apprehension about broader economic conditions impacting the sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2024 | $3M | -$2M | -$0.46 |
Based on FMP financials and quantitative analysis
THMO Latest News
No recent news available for THMO.
THMO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for THMO.
Price Targets
Wall Street price target analysis for THMO.
THMO MoonshotScore
What does this score mean?
The MoonshotScore rates THMO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Xiaochun Xu
CEO
Xiaochun Xu has extensive experience in the biomedical sector, having held various leadership positions in technology and healthcare companies. He has a strong educational background in biomedical engineering and has been instrumental in driving innovation and strategic growth within ThermoGenesis Holdings, Inc. His leadership style emphasizes collaboration and forward-thinking, positioning the company for future success.
Track Record: Under Xiaochun Xu's leadership, ThermoGenesis has successfully launched several key products in the automated cell processing market. His strategic decisions have focused on enhancing product offerings and expanding market reach, contributing to the company's evolving reputation in the healthcare sector.
THMO OTC Market Information
The OTC Other tier indicates that ThermoGenesis Holdings, Inc. is subject to less stringent reporting requirements compared to stocks listed on major exchanges like NYSE or NASDAQ. This can lead to lower visibility and potentially higher volatility, as companies in this tier may not be required to file regular financial reports.
- OTC Tier: OTC Other
- Limited liquidity can result in higher volatility and difficulty in buying or selling shares.
- Less stringent reporting requirements may lead to less transparency.
- Potential regulatory scrutiny as the company operates in a highly regulated industry.
- Verify the company's financial health through available reports.
- Assess the competitive landscape and market positioning.
- Monitor regulatory developments affecting the biomedical sector.
- Review product development timelines and market readiness.
- Evaluate management's track record and strategic vision.
- Established history since 1986 in the biomedical sector.
- Partnerships with reputable healthcare institutions.
- Presence in multiple international markets, indicating global reach.
Common Questions About THMO (Healthcare)
What does the AI Score mean for THMO?
THMO holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. ThermoGenesis Holdings, Inc. is a leading innovator in automated cell processing systems for medical applications. Founded in 1986, the company specializes in products that enhance cell banking …
What does ThermoGenesis Holdings, Inc. do?
ThermoGenesis Holdings, Inc. specializes in developing automated systems for cell banking and processing, focusing on innovative solutions for isolating stem cells and cryopreservation. Their product portfolio includes the AXP II Automated Cell Separation System and the BioArchive Automated Cryopreservation System, catering to hospitals, biobanks, and research institutions globally.
What are the main risks for THMO?
ThermoGenesis Holdings, Inc. faces several risks, including regulatory challenges that may delay product approvals and market entry. Additionally, the company has a high operational loss margin, which could affect its financial stability. Intense competition from larger companies in the medical device sector also poses a significant threat to its market share.
What revenue streams does ThermoGenesis Holdings, Inc. have in healthcare?
ThermoGenesis generates revenue primarily through the sale of its automated cell processing systems and medical devices. Additionally, the company offers contract development and manufacturing services for cell-based therapies, providing a diverse range of income sources. The company markets its products globally, focusing on regions with high demand for innovative healthcare solutions.
What are the key factors to evaluate for THMO?
ThermoGenesis Holdings, Inc. (THMO) holds an AI score of 49/100 (low). operates in a rapidly growing sector, with a focus on automated cell processing systems that are increasingly vital in healthcare. Not financial advice.
How frequently does THMO data refresh on this page?
THMO's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven THMO's recent stock price performance?
ThermoGenesis Holdings, Inc. (THMO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product line tailored for automated cell processing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider THMO overvalued or undervalued right now?
ThermoGenesis Holdings, Inc. (THMO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research THMO before investing?
Before investing in ThermoGenesis Holdings, Inc. (THMO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial metrics are based on the latest available data, but may be subject to change as new reports are released.